Last reviewed · How we verify
IV levofloxacin
IV levofloxacin is a Fluoroquinolone antibiotic Small molecule drug developed by Pfizer. It is currently FDA-approved for Community-acquired pneumonia, Acute bacterial sinusitis, Acute bacterial exacerbation of chronic bronchitis. Also known as: Levaquin®.
Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.
Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms. Used for Community-acquired pneumonia, Acute bacterial sinusitis, Acute bacterial exacerbation of chronic bronchitis.
At a glance
| Generic name | IV levofloxacin |
|---|---|
| Also known as | Levaquin® |
| Sponsor | Pfizer |
| Drug class | Fluoroquinolone antibiotic |
| Target | Bacterial DNA gyrase (topoisomerase II) and topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
As a fluoroquinolone antibiotic, levofloxacin is the active L-enantiomer of ofloxacin. It binds to and inhibits bacterial topoisomerases, enzymes essential for DNA unwinding and replication. This leads to accumulation of DNA breaks, cell death, and bactericidal activity against a broad spectrum of gram-positive and gram-negative bacteria.
Approved indications
- Community-acquired pneumonia
- Acute bacterial sinusitis
- Acute bacterial exacerbation of chronic bronchitis
- Complicated urinary tract infection
- Acute pyelonephritis
- Uncomplicated urinary tract infection
- Prostatitis
- Skin and soft tissue infections
Common side effects
- Nausea
- Diarrhea
- Headache
- Insomnia
- Tendinopathy
- QT prolongation
- Photosensitivity
- Peripheral neuropathy
Key clinical trials
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus (PHASE3)
- Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2) (PHASE3)
- STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis (PHASE3)
- Early Antibiotics After Aspiration in ICU Patients (PHASE4)
- Beta-lactam Plus Levofloxacin to Enhance Therapy in Streptococcal Septicemia (PHASE4)
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV levofloxacin CI brief — competitive landscape report
- IV levofloxacin updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about IV levofloxacin
What is IV levofloxacin?
How does IV levofloxacin work?
What is IV levofloxacin used for?
Who makes IV levofloxacin?
Is IV levofloxacin also known as anything else?
What drug class is IV levofloxacin in?
What development phase is IV levofloxacin in?
What are the side effects of IV levofloxacin?
What does IV levofloxacin target?
Related
- Drug class: All Fluoroquinolone antibiotic drugs
- Target: All drugs targeting Bacterial DNA gyrase (topoisomerase II) and topoisomerase IV
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Community-acquired pneumonia
- Indication: Drugs for Acute bacterial sinusitis
- Indication: Drugs for Acute bacterial exacerbation of chronic bronchitis
- Also known as: Levaquin®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing